With coronavirus cases surging in the United States, the need for a vaccine is growing increasingly urgent, but federal officials have sought in recent days to reassure the public that the approval process for any potential vaccine will be thorough and transparent. Pfizer and BioNTech announced Wednesday that the latest data from their vaccine study indicates their shot is 95% effective, and they intend to formally apply for emergency authorization (EUA) in the U.S. within days. The companies claimed no serious side effects had been detected, and the most common problem was fatigue reported by 4% of participants. To read the full story.
- A Decade of Progress: Addressing Humanity’s Shared Challenges.
- NJACTS Community Engagement Core Available Services
- Remote work has been a boon for people with disabilities. Will employers keep it going?
- Marijuana Component Offers Opioid Alternative by Effectively Treating Dental Pain.
- Join NJ ACTS Special Populations Core Seminar on December 5th at 12pm